STAT3-IN-52 hydrochloride
Based on 1 Customer Validation
STAT3-IN-52 hydrochloride is an orally active STAT3 inhibitor with a Ki value of 2.42 μM. STAT3-IN-52 hydrochloride binds directly and selectively to the pY705 site of STAT3 (Ki = 0.44 μM), thereby impairing its function. STAT3-IN-52 hydrochloride induces apoptosis and triggers anti-tumor responses in vivo. STAT3-IN-52 hydrochloride can be used in breast cancer-related research.
For research use only. We do not sell to patients.
- Purity : 96.42%
- Formula: C20H21ClN4O4S
- Molecular Weight:448.92
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
|
STAT3 2.42 μM (Ki) |
In Vitro
STAT3-IN-52 binds directly to fluorescently labeled purified STAT3 protein, with a Ki value of 2.42 μM at a ligand-to-protein molar ratio of 1:1[1].
STAT3-IN-52 (0-400 μM; 24 h) inhibits the viability of human normal mammary epithelial MCF-10A cells, with an IC50 of 128.9 μM, and its potency against normal cells is 184-fold lower than that against MDA-MB-231 cancer cells[1].
STAT3-IN-52 (0.1-10 μM; 24 h) inhibits the viability of human medulloblastoma (UW426, UW288-1), human pancreatic cancer (BKPC3), human osteosarcoma (U2OS), and mouse sarcoma (S180) cells, with an IC50 of 0.42 μM against S180 cells[1].
STAT3-IN-52 (5 μM; 0-24 h) time-dependently and selectively inhibits the DNA-binding activity of STAT3 homodimers in human basal-like breast cancer MDA-MB-231 cells, exerts weak effects on STAT1 dimer binding, and does not inhibit IFN-γ-induced STAT1 binding or STAT5 dimer binding[1].
STAT3-IN-52 reduces the mRNA expression of the oncogene MMP9 in human basal-like breast cancer MDA-MB-231 cells, but exerts no significant effect on the expression of the CDK2 gene in these cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human basal-like breast cancer MDA-MB-231 cells
-
Concentration:2.5, 5 and 10 μM
-
Incubation Time:12 h; 2 h pre-incubation before 30 min IL-6 stimulation
-
Result:Reduced the level of p-STAT3 (Y705) in a dose-dependent manner, without altering levels of acetylated STAT3 (K685), p-STAT3 (S727), total STAT3, p-AKT, or p-ERK1/2.
Inhibited IL-6-induced phosphorylation of STAT3, but did not inhibit p-STAT1 (Y701) or IFN-γ-induced phosphorylation of STAT1.
Increased the expression of SHP-1 and cleaved caspase-3.
In Vivo
STAT3-IN-52 (5 mg/kg; p.o.; daily; 21 days) orally reduces S180 sarcoma xenograft weight by 73% with minimal systemic toxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (6-week-old female, athymic SPF, subcutaneous xenograft of human MDA-MB-231 breast cancer cells)[1]
-
Dosage:2.5 mg/kg; 5 mg/kg; 10 mg/kg
-
Administration:p.o.; daily; 32 days
-
Result:Reduced tumor weight by 53% at 2.5 mg/kg, 60% at 5 mg/kg, and 70% at 10 mg/kg.
Showed normal body weight gain, with no damage to major organs (heart, liver, spleen, lung, kidney) detected via H&E staining.
Dose-dependently inhibited p-STAT3 (Y705) levels in tumor tissue, with no significant effect on total STAT3 levels, as confirmed by immunohistochemical analysis and Western blot.
-
Animal Model:ICR (4-week-old male, subcutaneous xenograft of mouse S180 sarcoma cells)[1]
-
Dosage:5 mg/kg
-
Administration:p.o.; daily; 21 days
-
Result:Reduced tumor weight by 73% after 21 days of treatment.
Showed normal body weight gain, in contrast to dramatic weight loss observed in doxorubicin-treated mice starting on day 13.
Organs (liver, spleen, kidney) were notably larger than those from doxorubicin-treated mice, indicating less toxicity.
Chemical Information
-
Appearance Solid
-
Molecular Weight 448.92
-
Formula C20H21ClN4O4S
-
Color Dark purple to black
-
SMILES
O=S(C(C=CC=C1C(C(NC2=CC=CC=C2N3CCNCC3)=C4)=O)=C1C4=O)(N)=O.Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 5 mg/mL (11.14 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.5 mg/mL (1.11 mM); Clear solution
This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.5 mg/mL (1.11 mM); Clear solution
This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (286 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2276 mL | 11.1378 mL | 22.2757 mL | 55.6892 mL |
| 5 mM | 0.4455 mL | 2.2276 mL | 4.4551 mL | 11.1378 mL | |
| 10 mM | 0.2228 mL | 1.1138 mL | 2.2276 mL | 5.5689 mL |
STAT3-IN-52 hydrochloride Related Classifications
HY-177990A Related Classifications
Powered by Bioz